MGluR3 knockout mice show a working memory defect and an enhanced response to MK-801 in the T- and Y-maze cognitive tests

Behavioural Brain Research

Volumn 266, Issue , 2014, Pages 94-103

  Lainiola, Mira ^a   Procaccini, Chiara ^a   Linden, Anni Maija ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Dizocilpine; Left right asymmetry; MGlu3 receptor; Mouse; Side bias; Working memory

Indexed keywords

DIZOCILPINE; METABOTROPIC RECEPTOR 3; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; METABOTROPIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; BRAIN ASYMMETRY; CIRCLING BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; DECISION MAKING; LOCOMOTION; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; T-MAZE TEST; WORKING MEMORY; Y-MAZE TEST; ANALYSIS OF VARIANCE; ANIMAL; CLASSIFICATION; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENETICS; HEMISPHERIC DOMINANCE; KNOCKOUT MOUSE; MAZE TEST; MEMORY DISORDERS; PHYSIOLOGY; SHORT TERM MEMORY;

ANALYSIS OF VARIANCE; ANIMALS; ATTENTION; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; FUNCTIONAL LATERALITY; MAZE LEARNING; MEMORY DISORDERS; MEMORY, SHORT-TERM; MICE; MICE, KNOCKOUT; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84896499254     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.03.008     Document Type: Article

References (55)

1. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005, 4:131-144.
2. Fell M.J., McKinzie D.L., Monn J.A., Svensson K.A. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 2012, 62:1473-1483.
3. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007, 13:1102-1107.
4. Dunayevich E., Erickson J., Levine L., Landbloom R., Schoepp D.D., Tollefson G.D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008, 33:1603-1610.
5. Kinon B.J., Gomez J.C. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia. Neuropharmacology 2013, 66:82-86.
6. Cartmell J., Schoepp D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 2000, 75:889-907.
7. Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Rev 1999, 29:83-120.
8. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol 1993, 335:252-266.
9. Tamaru Y., Nomura S., Mizuno N., Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 2001, 106:481-503.
10. Wright R.A., Johnson B.G., Zhang C., Salhoff C., Kingston A.E., Calligaro D.O., et al. CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [(3)H]LY459477 autoradiography. Neuropharmacology 2013, 66:89-98.
11. Harrison P.J., Lyon L., Sartorius L.J., Burnet P.W., Lane T.A. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 2008, 22:308-322.
12. Corti C., Battaglia G., Molinaro G., Riozzi B., Pittaluga A., Corsi M., et al. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci 2007, 27:8297-8308.
13. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15.
14. Amitai N., Markou A. Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-d-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol Psychiatry 2010, 68:5-16.
15. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010, 36:246-270.
16. O'Tuathaigh C.M., Harte M., O'Leary C., O'Sullivan G.J., Blau C., Lai D., et al. Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. Eur J Neurosci 2010, 31:349-358.
17. Allen J.A., Yadav P.N., Setola V., Farrell M., Roth B.L. Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo. Transl Psychiatry 2011, 1:e33.
18. Woolley M.L., Pemberton D.J., Bate S., Corti C., Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008, 196:431-440.
19. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2008, 326:209-217.
20. Egan M.F., Straub R.E., Goldberg T.E., Yakub I., Callicott J.H., Hariri A.R., et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 2004, 101:12604-12609.
21. Marenco S., Steele S.U., Egan M.F., Goldberg T.E., Straub R.E., Sharrief A.Z., et al. Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex. Am J Psychiatry 2006, 163:740-742.
22. Baune B.T., Suslow T., Beste C., Birosova E., Domschke K., Sehlmeyer C., et al. Association between genetic variants of the metabotropic glutamate receptor 3 (GRM3) and cognitive set shifting in healthy individuals. Genes Brain Behav 2010, 9:459-466.
23. Kawakubo Y., Suga M., Tochigi M., Yumoto M., Itoh K., Sasaki T., et al. Effects of metabotropic glutamate receptor 3 genotype on phonetic mismatch negativity. PLoS ONE 2011, 6:e24929.
24. Neale J.H., Olszewski R.T., Zuo D., Janczura K.J., Profaci C.P., Lavin K.M., et al. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J Neurochem 2011, 118:490-498.
25. Neale J.H. N-acetylaspartylglutamate is an agonist at mGluR(3) in vivo and in vitro. J Neurochem 2011, 119:891-895.
26. Zuo D., Bzdega T., Olszewski R.T., Moffett J.R., Neale J.H. Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia. J Biol Chem 2012, 287:21773-21782.
27. Walder K.K., Ryan S.B., Bzdega T., Olszewski R.T., Neale J.H., Lindgren C.A. Immunohistological and electrophysiological evidence that N-acetylaspartylglutamate is a co-transmitter at the vertebrate neuromuscular junction. Eur J Neurosci 2013, 37:118-129.
28. Olszewski R.T., Bukhari N., Zhou J., Kozikowski A.P., Wroblewski J.T., Shamimi-Noori S., et al. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 2004, 89:876-885.
29. Olszewski R.T., Bzdega T., Neale J.H. mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia. Schizophr Res 2012, 136:160-161.
30. Olszewski R.T., Janczura K.J., Ball S.R., Madore J.C., Lavin K.M., Lee J.C., et al. NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia. Transl Psychiatry 2012, 2:e145.
31. Yokoi M., Kobayashi K., Manabe T., Takahashi T., Sakaguchi I., Katsuura G., et al. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science 1996, 273:645-647.
32. Higgins G.A., Ballard T.M., Kew J.N., Richards J.G., Kemp J.A., Adam G., et al. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 2004, 46:907-917.
33. Linden A.M., Shannon H., Baez M., Yu J.L., Koester A., Schoepp D.D. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psychopharmacology (Berl) 2005, 179:284-291.
34. Linden A.M., Johnson B.G., Trokovic N., Korpi E.R., Schoepp D.D. Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495. Neuropharmacology 2009, 57:172-182.
35. Lyon L., Burnet P.W., Kew J.N., Corti C., Rawlins J.N., Lane T., et al. Fractionation of spatial memory in GRM2/3 (mGlu2/mGlu3) double knockout mice reveals a role for group II metabotropic glutamate receptors at the interface between arousal and cognition. Neuropsychopharmacology 2011, 36:2616-2628.
36. Gerlai R. A new continuous alternation task in T-maze detects hippocampal dysfunction in mice. A strain comparison and lesion study. Behav Brain Res 1998, 95:91-101.
37. Linden A.M., Sandu C., Aller M.I., Vekovischeva O.Y., Rosenberg P.H., Wisden W., et al. TASK-3 knockout mice exhibit exaggerated nocturnal activity, impairments in cognitive functions, and reduced sensitivity to inhalation anesthetics. J Pharmacol Exp Ther 2007, 323:924-934.
38. Redrobe J.P., Nielsen E.O., Christensen J.K., Peters D., Timmermann D.B., Olsen G.M. Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice. Eur J Pharmacol 2009, 602:58-65.
39. Thomsen M.S., Christensen D.Z., Hansen H.H., Redrobe J.P., Mikkelsen J.D. alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology 2009, 56:1001-1009.
40. Kurita M., Holloway T., Garcia-Bea A., Kozlenkov A., Friedman A.K., Moreno J.L., et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 2012, 15:1245-1254.
41. Fraser C.M., Cooke M.J., Fisher A., Thompson I.D., Stone T.W. Interactions between ifenprodil and dizocilpine on mouse behaviour in models of anxiety and working memory. Eur Neuropsychopharmacol 1996, 6:311-316.
42. Takahashi E., Niimi K., Itakura C. Impairment of spatial short-term memory following acute administration of the NMDA receptor antagonist in heterozygous rolling Nagoya mice carrying the Ca V 2.1 alpha1 mutation. Behav Brain Res 2010, 213:121-125.
43. van der Staay F.J., Rutten K., Erb C., Blokland A. Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behav Brain Res 2011, 220:215-229.
44. Takatsu Y., Fujita Y., Tsukamoto T., Slusher B.S., Hashimoto K. Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice. Brain Res 2011, 1371:82-86.
45. Janczura K.J., Olszewski R.T., Bzdega T., Bacich D.J., Heston W.D., Neale J.H. NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test. Eur J Pharmacol 2013, 701:27-32.
46. Profaci C.P., Krolikowski K.A., Olszewski R.T., Neale J.H. Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia. Psychopharmacology (Berl) 2011, 216:235-243.
47. Burket J.A., Cannon W.R., Jacome L.F., Deutsch S.I. MK-801, a noncompetitive NMDA receptor antagonist, elicits circling behavior in the genetically inbred Balb/c mouse strain. Brain Res Bull 2010, 83:337-339.
48. Ali S.F., Newport G.D., Bracha H.S. Phencyclidine and (+)-MK-801-induced circling preference: correlation with monoamine levels in striatum of the rat brain. Neurotoxicol Teratol 1994, 16:335-342.
49. Collins R.L. When left-handed mice live in right-handed worlds. Science 1975, 187:181-184.
50. Morice E., Denis C., Macario A., Giros B., Nosten-Bertrand M. Constitutive hyperdopaminergia is functionally associated with reduced behavioral lateralization. Neuropsychopharmacology 2005, 30:575-581.
51. Andrade C., Alwarshetty M., Sudha S., Suresh Chandra J. Effect of innate direction bias on T-maze learning in rats: implications for research. J Neurosci Methods 2001, 110:31-35.
52. Mackes J.L., Willner J. NMDA antagonist MK-801 impairs acquisition of place strategies, but not their use. Behav Brain Res 2006, 175:112-118.
53. Tan H.Y., Chen Q., Sust S., Buckholtz J.W., Meyers J.D., Egan M.F., et al. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc Natl Acad Sci USA 2007, 104:12536-12541.
54. Alary M., Delcroix N., Leroux E., Razafimandimby A., Brazo P., Delamillieure P., et al. Functional hemispheric lateralization for language in patients with schizophrenia. Schizophr Res 2013, 149:42-47.
55. Gruzelier J.H. Functional neuropsychophysiological asymmetry in schizophrenia: a review and reorientation. Schizophr Bull 1999, 25:91-120.